8-K
Coeptis Therapeutics Holdings, Inc. (COEP)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):December 20, 2023
_____________________
COEPTIS THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in itscharter)
| Delaware | 001-39669 | 98-1465952 |
|---|---|---|
| (State or other jurisdiction<br><br> <br>of incorporation) | (Commission<br><br> <br>File Number) | (I.R.S. Employer<br><br> <br>Identification No.) |
| 105 Bradford Rd, Suite 420<br><br> <br>Wexford, Pennsylvania | 15090 | |
| (Address of principal executive offices) | (Zip Code) |
724-934-6467
(Registrant’s telephone number, including area code)
____________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br> <br>Symbol(s) | Name of each exchange<br><br> <br>on which registered |
|---|---|---|
| Common Stock, par value $0.0001 per share | COEP | Nasdaq Capital Market |
| Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $11.50 per whole share | COEPW | Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 | Submission of Matters to a Vote of Security Holders |
|---|
On December 20, 2023, Coeptis Therapeutics Holdings, Inc. (the “Company”) held an Annual Meeting of Stockholders (the “Annual Meeting”).
At the Annual Meeting, the Company’s stockholders voted on the proposals set forth below, which are each described in greater detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on November 17, 2023 (the “Proxy Statement”). Of the 34,108,036 shares of the Company’s common stock outstanding as of the record date, 21,951,175 shares, or approximately 64.36%, were present virtually or represented by proxy at the Annual Meeting.
The final voting results for the matters submitted to a Company stockholder vote at the Annual Meeting are as follows:
| 1) | At the Meeting, the vote to elect seven (7) directors, was as follows: | ||
|---|---|---|---|
| FOR | WITHHELD | BROKER NON-VOTE | |
| --- | --- | --- | --- |
| David Mehalick | 18,999,713 | 8,419 | 2,943,043 |
| Daniel Yerace | 18,999,468 | 8,664 | 2,943,043 |
| Christopher Calise | 18,989,395 | 18,737 | 2,943,043 |
| Tara Maria DeSilva | 18,999,723 | 8,409 | 2,943,043 |
| Philippe Deschamps | 18,999,579 | 8,553 | 2,943,043 |
| Christopher Cochran | 18,984,781 | 23,351 | 2,943,043 |
| Gene Salkind | 18,994,614 | 13,518 | 2,943,043 |
| 2) | At the Meeting, the vote to ratify the appointment of Turner Stone & Company, LLP as the Company’s independent registered<br>public accounting firm for the fiscal year ending December 31, 2023, was as follows: | ||
| --- | --- | ||
| FOR | AGAINST | ABSTAIN | |
| --- | --- | --- | |
| 21,900,607 | 1,675 | 48,893 | |
| 3) | At the Meeting, the vote to approve, for the purpose of Nasdaq Marketplace Rule 5635(d), the issuance of shares of common stock underlying<br>warrants originally issued by the Company in June 2023 and October 2023, was as follows: | ||
| --- | --- | ||
| FOR | AGAINST | ABSTAIN | BROKER<br><br>NON-VOTE |
| --- | --- | --- | --- |
| 18,679,579 | 182,627 | 145,926 | 2,943,043 |
| 2 |
| --- | | 4) | At the Meeting, the vote to conduct a non-binding advisory vote to approve the compensation of the Company’s named executive<br>officers, was as follows: | | --- | --- | | FOR | AGAINST | ABSTAIN | BROKER<br><br>NON-VOTE | | --- | --- | --- | --- | | 18,544,258 | 413,037 | 50,837 | 2,943,043 | | 5) | At the Meeting, the vote to approve an amendment to the Company’s 2022 Equity Incentive Plan, as amended, or the 2022 Plan,<br>to add 5,000,000 shares for issuance under the 2022 Plan was as follows: | | --- | --- | | FOR | AGAINST | ABSTAIN | BROKER<br><br>NON-VOTE | | --- | --- | --- | --- | | 18,691,980 | 134,212 | 181,940 | 2,943,043 |
As there were sufficient votes to approve the above proposals, the “Adjournment Proposal” described in the Proxy Statement was not presented to stockholders.
| 3 |
| --- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Coeptis Therapeutics Holdings, Inc. | ||
|---|---|---|
| Date: December 22, 2023 | By: | /s/ David Mehalick |
| David Mehalick<br><br> <br>Chief Executive Officer |
| 4 |
| --- |